Biocept Inc. (NASDAQ: BIOC) stock gained by 4.24% at last close whereas the BIOC stock-price plunge by 7.59% in the pre-market trading session. Biocept creates and sells molecular diagnostic tests that offer clinicians with clinically useful information to help in the diagnosis, therapy, and follow-up of cancer patients.
BIOC stock’ Current Development
New research from Biocept shows that the company’s CNSide cerebrospinal fluid assay discovered tumor cells and detected actionable mutations in lung cancer patients with leptomeningeal carcinomatosis, enabling for tailored therapy options that might improve outcomes and lengthen life expectancy. The findings were to be presented as a poster at the Society for Neuro-(SNO) Oncology’s Third Annual Conference on Brain Metastases, held virtually on Aug. 19-20, 2021.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Clinical assessment, imaging, and cytology are the most common methods for diagnosing LMC, however they have poor sensitivity. The typical patient’s life expectancy is only four to six weeks if they are not treated.
The University of Utah Huntsman Cancer Institute employed Biocept’s CNSide test to identify and characterize tumor cells in the cerebrospinal fluid of 15 different individuals in a retrospective analysis. CNSide identified tumor cells in 100 percent of the samples examined with LMC, whereas cytology discovered tumor cells in just 40% of the samples. CNSide also discovered actionable indicators in tumor cells, allowing doctors to make tailored therapy decisions that decreased severe symptoms and, in some cases, increased patient survival by more than three years. The findings show that CNSide is more accurate than cytology, and that if an actionable target is found and medicated, patients with LMC can live longer.
Michael C. Dugan, BIOC Stock Chief Medical Officer and Medical Director stated,
It’s important to find actionable mutations while treating LMC patients. CNSide has shown that it can consistently identify and evaluate tumor cells in cerebrospinal fluid that aren’t present in blood or tissue samples. The precise molecular targets found in these tumor cells can lead a physician’s choice of newer, more effective treatments and impact the effectiveness of therapy in a way that can enable these patients achieve dramatic improvements in their symptoms and live much longer lives.